Catabasis Pharma (CATB) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Catabasis Pharmaceuticals Reports Second Quarter 2016 Financial Results and Recent Corporate Highlights
August 11, 2016 4:10 PM EDT-- Edasalonexent (CAT-1004) as a Potential Disease-Modifying Treatment for Duchenne Muscular Dystrophy (DMD): MoveDMD® Phase 2 (Part B) Trial Progressing Well and Open-Label Extension Initiated --
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2016... More
